OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

Peer-reviewed publications

Take a look at the Optune publications

Unprecedented 5-year survival data for newly diagnosed glioblastoma from the EF-14 trial published in JAMA

Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.

Journal of the American Medical Association

Stupp R, Taillibert S, Kanner A, et al.
2017;318(23):2­3­0­6­-­2­3­1­6.

Copyright 2017 American Medical Association. All rights reserved.

Click here to view the abstract

2017 article from The ASCO Post on the unprecedented 5-year survival results seen with Optune + TMZ in EF-14

‘Out-of-the-box’ approach plus temozolomide extends survival in glioblastoma.

The ASCO Post

Goodman A.
http://www.ascopost.com/issues/may-10-2017/out-of-the-box-approach-plus-temozolomide-extends-survival-in-glioblastoma. Updated May 10, 2017. Accessed December 7, 2020.

Click here to view the article

Landmark 5-year survival analysis of the EF-14 trial in newly diagnosed glioblastoma

Tumor Treating Fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multicenter, phase III trial.

2017 Annual Meeting of the American Association for Cancer Research (AACR)

Stupp R, Hegi ME, Idbaih A, et al.
2017; Abstract LBA AACR CT007.

Click here to view the abstract

Interim analysis of the EF-14 trial: Pivotal phase 3 data for newly diagnosed glioblastoma published in JAMA

Maintenance therapy with Tumor-Treating Fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial.

Journal of the American Medical Association

Stupp R, Taillibert S, Kanner AA, et al.
2015;314(23):2­5­3­5­-­2­5­4­3.

Copyright 2015 American Medical Association. All rights reserved.

Click here to view the article

The EF-11 trial: Pivotal phase 3 data for recurrent glioblastoma published in the European Journal of Cancer

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality

European Journal of Cancer

Stupp R, Wong ET, Kanner AA, et al.
2012;48(14):2­1­9­2­-­2­2­0­2.

Copyright 2012 Elsevier. All rights reserved.

Click here to download now

Management of dermatologic adverse events

Prevention and management of dermatologic adverse events associated with Tumor Treating Fields in patients with glioblastoma

Frontiers in Oncology

Lacouture ME, Anadkat MJ, Ballo MT, et al. 2020;10(1045):1-13. doi:10.3389/
fonc.2020.01045.

Copyright © 2020 Lacouture, Anadkat, Ballo, Iwamoto, Jeyapalan, La Rocca, Schwartz,
Serventi and Glas.

Click here to download now

Results from the NovoTAL™ System User Study

NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study

World Journal of Surgical Oncology

Chaudhry A, Benson L, Varshaver M, et al.
2015;13:316. doi: 10.1186/s1­2­9­5­7­-­0­1­5­-­0­7­2­2­-­3.

Click here to download now

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).